Maria Palasis
CIK 1810701 · Principal Executive Officer · last filed 2026-05-26
Maria Palasis is a Principal Executive Officer who has filed 28 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for BBNX, was dated May 26, 2026. Across all open-market trades the lifetime net is −$99.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $467.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$467.4K
2
28
-$99.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBNX | Director | 29,397 | $15.90 | $467.4K | -$79.4K | 6 | 2026-05-26 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | President & CEO | 1,096,733 | $0.70 | $767.8K | -$19.7K | 15 | 2026-01-08 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-26 | BBNX | Grant (A) | +16,965 | $0 | EDGAR |
| 2026-04-03 | — | Disp (D) | −2,000 | $0 | |
| 2026-01-27 | — | Notice (144) | −1,895 | -$3.2K | EDGAR |
| 2026-01-14 | BBNX | Grant (A) | +3,997 | $0 | EDGAR |
| 2026-01-08 | Lyra Therapeutics, Inc. (LYRA) Delisted | Sell (S) | −1,702 | -$5.7K | EDGAR |
| 2026-01-06 | — | Notice (144) | −1,702 | -$5.7K | EDGAR |
| 2025-12-02 | BBNX | Sell (S) | −1,406 | -$41.6K | EDGAR |
| 2025-11-05 | BBNX | Sell (S) | −1,406 | -$37.8K | EDGAR |
| 2025-10-31 | BBNX | Notice (144) | −2,812 | -$75.3K | EDGAR |
| 2025-10-14 | — | Notice (144) | −537 | -$3.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.